Could a common supplement slow Alzheimer's decline?

NCT ID NCT07741071

Not yet recruiting Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This trial tests whether nicotinamide riboside (NR), a form of vitamin B3, can slow the progression of early Alzheimer's disease. About 270 adults with early-stage Alzheimer's will take NR or a placebo daily for two years. Researchers will measure changes in memory, thinking, and daily functioning to see if NR has a protective effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nicotinamide riboside (NR), a dietary supplement, taken as 1000 mg capsules twice daily for 104 weeks.
What this could lead to: If successful, this could point toward a way to slow the progression of early Alzheimer's disease, potentially preserving memory and daily function for longer.
What could go wrong: This is a phase 2 trial, so results are preliminary. The supplement may not slow the disease, and long-term safety is still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE (AD)

Contacts and locations

Locations

Haraldsplass Deaconess Hospital

Bergen, 5009, Norway
Haukeland University Hospital

Bergen, 5021, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.